Data Affirms Avandia Cardiovascular Safety Profile
GlaxoSmithKline confirms that a letter to the editor summarizing additional Avandia cardiovascular safety data from several large-scale clinical trials was published online today in The Lancet.
This letter, written by Ronald L. Krall, MD, Chief Medical Officer of GlaxoSmithKline, provides the necessary context and clarifies the safety record of Avandia, which is based on sound science and backed by one of the largest research programs ever in diabetes.
Key data points include:
-- The recent meta-analysis published in New England Journal of Medicine, which has been widely cited in media reports, omitted the total percentage number of events.